The Spanish VC firm Clave Capital has just reached a first close of around €50 million for its Clave Innohealth fund, which seeks to invest in startups and innovative projects with high growth potential in the healthcare sector.
The fund, which has a target size of €65 million and a hard cap of €80 million, has obtained commitments from investors such as CDTI, through its lnnvierte program, as well as family offices linked to the health sector, pharmaceutical laboratories, financial investors, and academic institutions linked to the health sector.
Clave Innohealth fund, which is regulated by the CNMV and is aimed at professional investors such as industrial groups, corporate ventures, funds of funds and family offices, will continue to raise funds until it reaches its target size.
The new fund aims to invest in around 30 companies, from early stage to series A financing rounds, with initial contributions of between €500k and €1 million, with the possibility of follow-on investments reaching €2-3 million per project. After a first close, Clave Innohealth fund is now operational and is actively seeking opportunities in sectorial segments such as Medtech, Digital Health, Health-Nutrition and Biotech.
Clave Capital has already made the first investment from the Clave Innohealth fund after leading a financing round in Innitius, a startup focused on improving diagnostics for women’s health. Innitius is currently conducting clinical trials with its first product, FineBirth, a test that uses artificial intelligence to help gynecologists make decisions regarding the diagnosis of premature births.
Clave Capital’s management team has more than 20 years of experience investing, building and accompanying more than 90 technology projects from their initial stages of construction. In the healthcare sector, Clave Capital has more than 20 investees in different research centers and hospitals, with an investment model confirmed and validated by the main players in the ecosystem and a close relationship with the main centers and environments that generate innovative projects in the healthcare sector.
The VC firm has successfully completed its first divestments and several of its investee companies have received new investors, which has led to a significant revalorization of Clave’s portfolio.
José Javier Armendariz, Clave Capital Chairman and CEO stated: “Clave Innohealth fund aims to be a reference in the healthcare sector at a national level, focusing its investment on innovative projects with the potential to be future market leaders both in Spain and internationally from their early stages,” said José Javier Armendariz, Chairman and CEO of Clave Capital.”
Clave Capital’s director of funds Santiago Lozano added: “There is currently an exciting opportunity to support the development of innovation in the healthcare sector in Spain while generating attractive financial returns. We have spent years developing and consolidating an investment model that is characterized by the fact that we not only provide money, but also accompany the companies in our portfolio with knowledge, expertise and contacts, helping them to become leaders in their sector, thanks to our positioning and extensive track record in the market, built around a multidisciplinary team with a long track record in healthtech investments.”